The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Akulova A.I.

V.I. Razumovsky Saratov State Medical University

Rebrov A.P.

V.I. Razumovsky Saratov State Medical University

Nikitina N.M.

V.I. Razumovsky Saratov State Medical University

Treatment of Spondyloarthritis in Real Clinical Practice: Focus on Interleukin-17 Blockers

Authors:

Akulova A.I., Rebrov A.P., Nikitina N.M.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2026;28(2): 78‑84

DOI: 10.17116/profmed20262902178

Read: 263 times

Download PDF (RU)
Contact the author
Table of contents

TREATMENT OF SPONDYLOARTHRITIS IN REAL CLINICAL PRACTICE: FOCUS ON INTERLEUKIN-17 BLOCKERS
TREATMENT OF SPONDYLOARTHRITIS IN REAL CLINICAL PRACTICE: FOCUS ON INTERLEUKIN-17 BLOCKERS

To cite this article:

Akulova AI, Rebrov AP, Nikitina NM. Treatment of Spondyloarthritis in Real Clinical Practice: Focus on Interleukin-17 Blockers. Russian Journal of Preventive Medicine. 2026;28(2):78‑84. (In Russ.)
https://doi.org/10.17116/profmed20262902178

Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Diagnostic accu­racy of the aging males’ symptoms questionnaire for screening androgen defi­ciency in patients with psoriatic arthritis. Russian Journal of Preventive Medi­cine. 2025;(5):27-33
Pharmacoeconomic analysis of the neta­kimab use for the treatment of psoriasis vulgaris in the health care settings of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):99-105
Persistence of skin process remi­ssion in patients with mode­rate and severe psoriasis vulgaris in application of neta­kimab: a five-year obse­rvational study resu­lts. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):462-468
Deve­lopment of a predictive model for the identification of patients with high risk of psoriatic arthritis and asse­ssment of the effi­cacy of early treatment with neta­kimab, IL-17A inhi­bitor. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):625-634
Analysis of the use of GEBD in a group of patients with psoriasis (according to the data from the Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Moscow Healthcare Depa­rtment). Russian Journal of Clinical Dermatology and Vene­reology. 2026;(1):53-62
Abstract:

OBJECTIVE

To analyze the administration of interleukin-17 inhibitors to patients with spondyloarthritis in the Saratov region and to assess the features of prescription and survival of therapy with secukinumab in real-life clinical practice.

MATERIALS AND METHODS

The medical records of 158 patients, who were treated in the rheumatological department of the «Regional Clinical Hospital» of Saratov between 2020 and October 2024, to whom interleukin-17 (IL-17) inhibitors were prescribed according to the council for administering the genetically engineered and targeted therapy. At the next stage, the features of the disease course and therapy survival in patients receiving one of IL-17 inhibitors (secukinumab) were analyzed.

RESULTS

The mean duration of treatment with secukinumab at the time of analysis was 27.0 [13.5; 35.5] months. During the year of observation, 23.7% of patients were withdrawn or switched to another genetically engineered biological drug (GEBD) or targeted agent: due to primary failure in 13 (13.4%) cases, due to secondary drug failure — in 6 (6.1%) cases. Drug withdrawal/change occurred in 21.4% of patients who received secukinumab as the first GEBD and in 29.6% of non-biologic-naive patients.

CONCLUSION

The study showed a high survival rate of the treatment with secukinumab in patients from the Saratov region, especially in biologic-naive patients. In addition, a tendency to more frequent withdrawal of this drug in patients who had previously used other genetically engineered biological drugs or targeted therapy was noted. However, patients in this group also had the high survival rate for the treatment with secukinumab.

Keywords:

axial spondyloarthritis
ankylosing spondylitis
psoriatic arthritis
genetically engineered therapy
interleukin-17 inhibitors
secukinumab
therapy survival

Authors:

Akulova A.I.

V.I. Razumovsky Saratov State Medical University

Rebrov A.P.

V.I. Razumovsky Saratov State Medical University

Nikitina N.M.

V.I. Razumovsky Saratov State Medical University

Received:

11.10.2025

Accepted:

24.11.2025

Close metadata

References:

  1. Jani M, Dixon WG, Chinoy H. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatology (Oxford). 2018; 57(11):1896-1907. https://doi.org/10.1093/rheumatology/kex434
  2. Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the Rheumatic Diseases. 2024;83(6):706-719.  https://doi.org/10.1136/ard-2024-225531
  3. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285-1299. https://doi.org/10.1002/acr.24025
  4. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Annals of the Rheumatic Diseases. 2023;82(1):19-34.  https://doi.org/10.1136/ard-2022-223296
  5. Klinicheskie rekomendacii. Psoriaz artropaticheskij. Psoriaticheskij artrit. 2024. Odobreno Nauchno-prakticheskim Sovetom Minzdrava Rossii. Accessed December 17, 2025. (In Russ.). https://diseases.medelement.com/disease/%D0%BF%D1%81%D0%BE%D1%80%D0%B8%D0%B0%D0%B7-%D0%B0%D1%80%D1%82%D1%80%D0%BE%D0%BF%D0%B0%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B9-%D0%BF%D1%81%D0%BE%D1%80%D0%B8%D0%B0%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B9-%D0%B0%D1%80%D1%82%D1%80%D0%B8%D1%82-%D0%BA%D0%BF-%D1%80%D1%84-2024/18297
  6. Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatry rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-prakticheskaya revmatologiya. 2017;55(1):68-86. (In Russ.). https://doi.org/10.14412/1995-4484-2017-68-86
  7. Blair HA. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2021;81(4): 483-494.  https://doi.org/10.1007/s40265-021-01476-3
  8. Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. American Journal of Clinical Dermatology. 2015;16(4):323-330.  https://doi.org/10.1007/s40257-015-0143-7
  9. Blair HA. Secukinumab: A Review in Ankylosing Spondylitis. Drugs. 2019; 79(4):433-443.  https://doi.org/10.1007/s40265-019-01075-3
  10. Igolkina EV, Chichasova NV. The survival rate of therapy with tumor necrosis factor-α inhibitors: main causes and drug substitution tactics. Sovremennaya revmatologiya. 2018;12(4):23-31. (In Russ.). https://doi.org/10.14412/1996-7012-2018-4-23-31
  11. Shapina MV. Long-term efficacy and survival of ustekinumab therapy in patients with inflammatory bowel disease. Meditsinskiy sovet. 2024;18(15): 166-172. (In Russ.). https://doi.org/10.21518/ms2024-399
  12. Ruscitti P, Pantano I, Perrotta FM, et al. The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort. Clinical and Experimental Rheumatology. 2024;42(1):69-76.  https://doi.org/10.55563/clinexprheumatol/tpp63h
  13. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis and Rheumatology. 1984;27(4):361-368.  https://doi.org/10.1002/art.1780270401
  14. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis and Rheumatology. 2006;54(8):2665-2673. https://doi.org/10.1002/art.21972
  15. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. Journal of Rheumatology. 1994;21(12):2286-2291.
  16. Lukas C, Lendew R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patient with ankylosing spondylitis. Annals of the Rheumatic Diseases. 2009;68(1):18-24.  https://doi.org/10.1136/ard.2008.094870
  17. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases. 2016;75(3):499-510.  https://doi.org/10.1136/annrheumdis-2015-208337
  18. Pinto AS, Farisogullari B, Machado PM. Predictors of remission in people with axial spondyloarthritis: A systematic literature review. Seminars in Arthritis and Rheumatism. 2022;56:152078. https://doi.org/10.1016/j.semarthrit.2022.152078
  19. Klinicheskie rekomendatsii. Uveity neinfektsionnye. 2024. Odobreno Nauchno-prakticheskim Sovetom Minzdrava RF. Accessed December 17, 2025. (In Russ.).
  20. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777-787.  https://doi.org/10.1016/j.ophtha.2012.09.040
  21. Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Practice and Research. Clinical Rheumatology. 2017;31(6):846-862.  https://doi.org/10.1016/j.berh.2018.08.002
  22. Lindström U, Bengtsson K, Olofsson T, et al. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter? Annals of the Rheumatic Diseases. 2021;80(11):1445-1452. https://doi.org/10.1136/annrheumdis-2021-220420
  23. Deodhar AA, Miceli-Richard C, Baraliakos X, et al. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR Open Rheumatology. 2020;2(5): 294-299.  https://doi.org/10.1002/acr2.11139
  24. Rodríguez Moncada R, Vázquez Morón JM, Pallarés Manrique H. The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease? Revista Espanola de Enfermedades Digestivas. 2019;111(9):720-721.  https://doi.org/10.17235/reed.2019.5841/2018
  25. Fauny M, Moulin D, D’Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Annals of the Rheumatic Diseases. 2020;79(9): 1132-1138. https://doi.org/10.1136/annrheumdis-2020-217927
  26. Uchida S, Oiso N, Komeda Y, et al. Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis. European Journal of Dermatology. 2019;29(4):444-445.  https://doi.org/10.1684/ejd.2018.3391
  27. Fernández-de la Varga M, Del Pozo-Del Valle P, Béjar-Serrano S, et al. Secukinumab-induced ulcerative colitis: opening Pandora’s box of immunity. Gastroenterology and Hepatology. 2020;43(7):358-359.  https://doi.org/10.1016/j.gastre.2019.12.003
  28. Lytkina KA, Lukina GV, Koltsova EN et al. Biologic therapy survival in patients with psoriatic arthritis. RMJ. Medicinskoe obozrenie. 2019;11(II):86-89. (In Russ.).
  29. Ruscitti P, Pantano I, Perrotta FM, et al. The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort. Clinical and Experimental Rheumatology. 2024;42(1):69-76.  https://doi.org/10.55563/clinexprheumatol/tpp63h
  30. Bounas A, Kandyli A, Katsifi G, et al. High long-term retention rates of Secukinumab in psoriatic arthritis and ankylosing spondylitis: a 3-year interim analysis from the observational, prospective SERENA study, in Greek patients. Rheumatology International. 2025;45:105.  https://doi.org/10.1007/s00296-025-05839-x
  31. Glintborg B, Østergaard M, Krogh NS, et al. Clinical Response, Drug Survival and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor and Inhibitor Therapy. Results from Danish Nationwide Registry. Arthritis αnd Rheumatism. 2013;65(5):1213-1223. https://doi.org/10.1002/art.37876
  32. Brahe CH, Ørnbjerg LM, Jacobsson L, et al. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. Rheumatology (Oxford). 2020;59(7):1640-1650. https://doi.org/10.1093/rheumatology/kez427
  33. Sun R, Bustamante M, Gurusamy VK, et al. Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials. Dermatology and Therapy. 2024;14:729-743.  https://doi.org/10.1007/s13555-024-01122-2
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.